Bruce C. Cozadd Sells 2,000 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 2,000 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the transaction, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at approximately $51,742,619.25. This represents a 0.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Jazz Pharmaceuticals Trading Down 0.3 %

Shares of JAZZ stock opened at $123.14 on Friday. The company has a 50-day moving average of $115.95 and a two-hundred day moving average of $111.46. The firm has a market cap of $7.45 billion, a PE ratio of 17.34, a price-to-earnings-growth ratio of 1.03 and a beta of 0.57. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. TD Cowen dropped their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Robert W. Baird upped their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research note on Monday, November 18th. JPMorgan Chase & Co. increased their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a report on Monday, August 19th. Piper Sandler restated an “overweight” rating and set a $163.00 target price (down from $166.00) on shares of Jazz Pharmaceuticals in a report on Thursday, November 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, November 21st. Three equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $175.33.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC raised its position in Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 97 shares during the period. GAMMA Investing LLC raised its holdings in shares of Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 116 shares during the period. Arizona State Retirement System lifted its stake in Jazz Pharmaceuticals by 0.8% during the 2nd quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock worth $1,770,000 after acquiring an additional 130 shares in the last quarter. Coldstream Capital Management Inc. boosted its holdings in Jazz Pharmaceuticals by 7.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock valued at $259,000 after acquiring an additional 165 shares during the period. Finally, Itau Unibanco Holding S.A. grew its position in Jazz Pharmaceuticals by 63.2% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after acquiring an additional 172 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.